Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Novo Nordisk and Glooko Partner to Improve Diabetes Management


Blood Glucose

The pharmaceutical company will apply Glooko’s FDA-cleared, HIPPA-compliant platform to develop an app designed to help diabetic patients improve their blood glucose control.

Share this!

January 10, 2017 | by Sarah Hand, M.Sc.

Danish diabetes drugmaker, Novo Nordisk, has partnered with mHealth company, Glooko, to develop patient-centric apps for better diabetes management. The pharmaceutical company will apply Glooko’s FDA-cleared, HIPPA-compliant platform to develop an app designed to help diabetic patients improve their blood glucose control.

Novo Nordisk is the world’s leading supplier of diabetes medications. The partnership will provide California-based Glooko with access to Novo Nordisk’s customer information, along with its diabetes-based educational resources.

“We will add that [content] to our mobile platform,” Glooko CEO Rick Altinger told MedCity News. “The vision is to leverage data to drive better and faster decisions to help patients and their caregivers get to better outcomes.”

Glooko’s diabetes management platform has allowed the company to collect patient data on about one million diabetic patients globally. In addition, over 4,800 health systems have adopted the technology for disease management and remote patient monitoring.

According to Altinger, Glooko not only helps patients track all of the variables that affect their diabetes management, but it also offers companies a way to add diabetes information into electronic health records (EHR). “Diabetes is a data-driven disease, said Altinger. “Health systems can pull in data from Glooko, into workflows and integrate with EHRs if they want.”

Aside from this most recent deal with Novo Nordisk, Glooko has already established deals with diabetes medical device makers, including Roche. As the agreement with Novo Nordisk is nonexclusive, the company’s partnership with IBM Watson Health will likely also come into play.

“We are excited to partner with Glooko and to take another step towards delivering digital health offerings that help people with diabetes to improve their blood glucose control,” said Christian Kanstrup, Novo Nordisk’s senior vice president for strategy, access and marketing. “Working in partnerships will furthermore enhance our ability to demonstrate the real-world value of our portfolio of diabetes treatments.”

While it’s unclear exactly what products will come out of the partnership, Glooko has said that personalized support for diabetic patients and their caregivers is the major goal. The first digital health offering could be made available before the end of this year.

Keywords: Diabetes, mHealth, Disease Management


Share this with your colleagues!

Lavazza Acquires Controlling Stake in Canada’s Kicking Horse Coffee

May 26, 2017 - Italian coffee company Lavazza, has secured an 80 percent equity stake in Canadian organic and fair-trade coffee company Kicking Horse Coffee, in a deal worth CAD$215 million.

Featured In: Food News

FDA First: Keytruda Approved for Cancer Treatment Based on Biomarker Alone

May 25, 2017 - For the first time, the FDA has approved a cancer treatment for solid tumors based on the presence of a biomarker, as opposed to specifying a tissue of origin.

Featured In: Biotech News

One Year of Medically Assisted Dying in Canada

May 25, 2017 - In June of 2016, the federal government of Canada passed legislation to legalize medically assisted dying.

Featured In: Life Science News


Top 5 Most Impactful Tweets in Life Sciences During the Last Week


EU IVD Regulation: Top Five Changes for Medical Device Manufacturers to Consider

Thermal Processing Systems for the Food Industry: A Guide to Selecting Thermal Equipment and Technology

Rare Disease & Orphan Drug Development: Cost-Efficient Trial Design to Minimize Cash Burn

eTMF Workflows: Active eTMF to Improve the Quality of Clinical Trials

Copyright © 2016-2017 Honeycomb Worldwide Inc.